Solutions to improve access to medicines and biomedical innovation through EU trade and R&D policy

The European Union’s (EU) free trade and research and development (R&D) policies promote excessive intellectual property (IP) protection. This approach jeopardises access to affordable, needed medicines and impedes needs-driven biomedical innovation.
Médecins Sans Frontières Access Campaign and our partners at HAI Europe and Oxfam are offering policy-makers seven straight-forward solutions that could transform harmful trade and R&D policy. By taking these solutions on board, the EU could enhance medicines access and pharmaceutical innovation in the EU and around the world.
Solutions to improve A2M and biomedical innovation.pdf
Page updated: 24 November 2014
↑ To top

Lives on the edge - patient needs are not driving medical research and development, and the result is millions of lives on the edge.